Jennifer Munkley
Overview
Explore the profile of Jennifer Munkley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siachisumo C, Luzzi S, Aldalaqan S, Hysenaj G, Dalgliesh C, Cheung K, et al.
Elife
. 2024 Oct;
12.
PMID: 39356106
Previously, we showed that the germ cell-specific nuclear protein RBMXL2 represses cryptic splicing patterns during meiosis and is required for male fertility (Ehrmann et al., 2019). Here, we show that...
2.
Goode E, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272811
Prostate cancer is a lethal solid malignancy and a leading cause of cancer-related deaths in males worldwide. Treatments, including radical prostatectomy, radiotherapy, and hormone therapy, are available and have improved...
3.
Hodgson K, Orozco-Moreno M, Goode E, Fisher M, Garnham R, Beatson R, et al.
EBioMedicine
. 2024 May;
104:105163.
PMID: 38772281
Background: Bone metastasis is a common consequence of advanced prostate cancer. Bisphosphonates can be used to manage symptoms, but there are currently no curative treatments available. Altered tumour cell glycosylation...
4.
Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt E, et al.
Commun Biol
. 2024 Mar;
7(1):276.
PMID: 38448753
Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and prostate to promote immune...
5.
Orozco-Moreno M, Visser E, Hodgson K, Hipgrave Ederveen A, Bastian K, Goode E, et al.
Glycobiology
. 2023 Oct;
33(12):1155-1171.
PMID: 37847613
Aberrant glycosylation is a hallmark of cancer and is not just a consequence, but also a driver of a malignant phenotype. In prostate cancer, changes in fucosylated and sialylated glycans...
6.
Hodgson K, Orozco-Moreno M, Scott E, Garnham R, Livermore K, Thomas H, et al.
Sci Rep
. 2023 Oct;
13(1):17031.
PMID: 37813880
Prostate cancer is the most common cancer in men and a major cause of cancer related deaths worldwide. Nearly all affected men develop resistance to current therapies and there is...
7.
Advani R, Luzzi S, Scott E, Dalgliesh C, Weischenfeldt J, Munkley J, et al.
Oncogene
. 2023 Sep;
42(43):3161-3168.
PMID: 37752235
Prostate cancer progression is connected to the activity of conventional oncogenes and tumour suppressors and driven by circulating steroid hormones. A key issue has been how to identify and care...
8.
Scott E, Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, et al.
J Pathol
. 2023 Aug;
261(1):71-84.
PMID: 37550801
Aberrant glycosylation is a universal feature of cancer cells, and cancer-associated glycans have been detected in virtually every cancer type. A common change in tumour cell glycosylation is an increase...
9.
Goode E, Wang N, Munkley J
Oncol Lett
. 2023 Mar;
25(4):163.
PMID: 36960185
Prostate cancer (PCa) is one of the most prominent causes of cancer-related mortality in the male population. A highly impactful prognostic factor for patients diagnosed with PCa is the presence...
10.
Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al.
Oncogene
. 2023 Feb;
42(12):926-937.
PMID: 36725887
Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need...